LYEL insider filings

Lyell Immunopharma, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-12. Screen LYEL transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 12 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
ARCH Venture Fund XIII, L.P. — 10% owner & ARCH Venture Partners XIII, L.P. — 10% owner & ARCH Venture Partners XIII, LLC — 10% owner & CRANDELL KEITH — 10% owner & GILLIS STEVEN — 10% owner & NELSEN ROBERT — 10% owner & Burow Kristina — 10% owner & BERNS PAUL L — 10% owner & BYBEE CLINTON — 10% owner11 leg · 2,321,262 sh · $24,999,992——
ARCH Venture Partners IX, LLC — 10% owner & ARCH Venture Fund IX, L.P. — 10% owner & ARCH Venture Partners IX, L.P. — 10% owner & ARCH Venture Fund IX Overage, L.P. — 10% owner & ARCH Venture Partners IX Overage, L.P. — 10% owner11 leg · 2,321,262 sh · $24,999,992——
Seely Lynn — President and CEO, Director2—2 legs · 10,134 sh · $157,695—
Lee Gary K. — Chief Scientific Officer2—2 legs · 1,586 sh · $24,697—
Hill Stephen J. — Chief Operating Officer2—2 legs · 1,077 sh · $16,771—
Bulis Veronica Sanchez — VP, Corporate Controller1—1 leg · 416 sh · $6,627—
Shook David — Chief Medical Officer1—1 leg · 500 sh · $6,350—
Aguirre Jarrad Mattieu — Chief Medical Officer2—1 leg · 422 sh · $3,6421

Recent insider filings — Lyell Immunopharma, Inc.

FiledFormInsiderReported transactionsSource
2026-11-124Hill Stephen J. — Chief Operating OfficerSale (S): 88 @ $15.93EDGAR
2026-11-124Lee Gary K. — Chief Scientific OfficerSale (S): 129 @ $15.93EDGAR
2026-11-124Bulis Veronica Sanchez — VP, Corporate ControllerSale (S): 416 @ $15.93EDGAR
2026-11-124Seely Lynn — President and CEO, DirectorSale (S): 545 @ $15.93EDGAR
2026-11-054ARCH Venture Partners IX, LLC — 10% owner
ARCH Venture Fund IX, L.P. — 10% owner
ARCH Venture Partners IX, L.P. — 10% owner
ARCH Venture Fund IX Overage, L.P. — 10% owner
ARCH Venture Partners IX Overage, L.P. — 10% owner
Purchase (P): 2,321,262 @ $10.77EDGAR
2026-11-054ARCH Venture Fund XIII, L.P. — 10% owner
ARCH Venture Partners XIII, L.P. — 10% owner
ARCH Venture Partners XIII, LLC — 10% owner
CRANDELL KEITH — 10% owner
GILLIS STEVEN — 10% owner
NELSEN ROBERT — 10% owner
Burow Kristina — 10% owner
BERNS PAUL L — 10% owner
BYBEE CLINTON — 10% owner
Purchase (P): 2,321,262 @ $10.77EDGAR
2026-10-134Aguirre Jarrad Mattieu — Chief Medical OfficerSale (S): 422 @ $8.63EDGAR
2026-09-104Shook David — Chief Medical OfficerSale (S): 500 @ $12.70EDGAR
2026-09-104Aguirre Jarrad Mattieu — Chief Medical OfficerGrant/award (A): 47,500 (derivative) @ $0EDGAR
2026-08-254Lee Gary K. — Chief Scientific OfficerSale (S): 1,457 @ $15.54EDGAR
2026-08-254Hill Stephen J. — Chief Operating OfficerSale (S): 989 @ $15.54EDGAR
2026-08-254Seely Lynn — President and CEO, DirectorSale (S): 9,589 @ $15.54EDGAR
2026-08-114Bulis Veronica Sanchez — VP, Corporate ControllerSale (S): 621 @ $14.34EDGAR
2026-08-114Lee Gary K. — Chief Scientific OfficerSale (S): 131 @ $14.34EDGAR
2026-08-114Hill Stephen J. — Chief Operating OfficerSale (S): 89 @ $14.34EDGAR
2026-08-114Seely Lynn — President and CEO, DirectorSale (S): 390 @ $14.34EDGAR
2026-07-274Innovative Cellular Therapeutics Holdings Ltd — 10% ownerOther (J): 44,000 @ $0EDGAR
2026-07-274Innovative Cellular Therapeutics Holdings Ltd — 10% ownerOther (J): 38,500 @ $0EDGAR
2026-07-204Innovative Cellular Therapeutics Holdings Ltd — 10% ownerSale (S): 10 @ $13.70EDGAR
2026-07-174Innovative Cellular Therapeutics Holdings Ltd — 10% ownerSale (S): 10 @ $13.73EDGAR
2026-07-014Innovative Cellular Therapeutics Holdings Ltd — 10% ownerOther (J): 76,000 @ $0EDGAR
2026-06-184Innovative Cellular Therapeutics Holdings Ltd — 10% ownerOther (J): 66,500 @ $0EDGAR
2026-06-154Bulis Veronica Sanchez — VP, Corporate ControllerSale (S): 217 @ $18.91EDGAR
2026-06-154Lee Gary K. — Chief Scientific OfficerSale (S): 130 @ $18.92EDGAR
2026-06-154Hill Stephen J. — Chief Operating OfficerSale (S): 89 @ $18.92EDGAR
2026-06-154Seely Lynn — President and CEO, DirectorSale (S): 388 @ $18.91EDGAR
2026-06-124Bachleda Mark — DirectorGrant/award (A): 9,250 (derivative) @ $0EDGAR
2026-06-124NABEL ELIZABETH G — DirectorGrant/award (A): 9,250 (derivative) @ $0EDGAR
2026-06-124Klausner Richard — DirectorGrant/award (A): 9,250 (derivative) @ $0EDGAR
2026-06-124Ramachandra Sumant — DirectorGrant/award (A): 9,250 (derivative) @ $0EDGAR
2026-06-124FRIEDMAN CATHY — DirectorGrant/award (A): 9,250 (derivative) @ $0EDGAR
2026-06-124BRAWLEY OTIS W — DirectorGrant/award (A): 9,250 (derivative) @ $0EDGAR
2026-06-124RIEFLIN WILLIAM JL — DirectorGrant/award (A): 9,250 (derivative) @ $0EDGAR
2026-06-114Shook David — Chief Medical OfficerSale (S): 1,977 @ $12.64EDGAR
2026-03-164Shah Smital — Chief Fin. and Bus. OfficerGrant/award (A): 140,000 (derivative) @ $0EDGAR
2026-03-094ARCH Venture Partners IX, LLC — 10% owner
ARCH Venture Partners IX, L.P. — 10% owner
ARCH Venture Partners IX Overage, L.P. — 10% owner
ARCH Venture Fund IX, L.P. — 10% owner
ARCH Venture Fund IX Overage, L.P. — 10% owner
Purchase (P): 488,090 @ $25.61EDGAR
2026-03-094ARCH Venture Fund XIII, L.P. — 10% owner
ARCH Venture Partners XIII, L.P. — 10% owner
ARCH Venture Partners XIII, LLC — 10% owner
CRANDELL KEITH — 10% owner
NELSEN ROBERT — 10% owner
Burow Kristina — 10% owner
GILLIS STEVEN — 10% owner
BERNS PAUL L — 10% owner
BYBEE CLINTON — 10% owner
Purchase (P): 488,090 @ $25.61EDGAR
2026-02-124Lee Gary K. — Chief Scientific OfficerSale (S): 1,671 @ $23.39EDGAR
2026-02-124Hill Stephen J. — Chief Operating OfficerSale (S): 1,236 @ $23.39EDGAR
2026-02-124Seely Lynn — President and CEO, DirectorSale (S): 7,455 @ $23.39EDGAR
2026-02-114Bulis Veronica Sanchez — VP, Corporate ControllerGrant/award (A): 8,750 @ $0 · Sale (S): 254 @ $23.12EDGAR
2026-02-114Shook David — Chief Medical OfficerGrant/award (A): 50,000 (derivative) @ $0EDGAR
2026-02-114Lee Gary K. — Chief Scientific OfficerGrant/award (A): 4,000 @ $0 · Sale (S): 147 @ $23.12 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2026-02-114Hill Stephen J. — Chief Operating OfficerGrant/award (A): 4,000 @ $0 · Sale (S): 109 @ $23.12 · Grant/award (A): 65,000 (derivative) @ $0EDGAR
2026-02-114Meltz Mark A — General CounselGrant/award (A): 50,000 (derivative) @ $0EDGAR
2026-02-114Seely Lynn — President and CEO, DirectorGrant/award (A): 20,000 @ $0 · Sale (S): 438 @ $23.12 · Grant/award (A): 155,000 (derivative) @ $0EDGAR
2026-01-064Bulis Veronica Sanchez — VP, Corporate ControllerSale (S): 1,136 @ $38.67 · Sale (S): 936 @ $32.32EDGAR
2025-11-124Lee Gary K. — Chief Scientific OfficerSale (S): 138 @ $16.16EDGAR
2025-11-124Hill Stephen J. — Chief Operating OfficerSale (S): 95 @ $16.12EDGAR
2025-11-124Seely Lynn — President and CEO, DirectorSale (S): 412 @ $16.11EDGAR

Recent 8-K events — Lyell Immunopharma, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-048-K3.02 — Unregistered Sales of Equity SecuritiesEDGAR
2026-11-048-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-108-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-158-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-098-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-088-K8.01 — Other EventsEDGAR
2025-12-058-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=LYEL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs